Travere Therapeutics (TVTX) Earnings Date, Estimates & Call Transcripts → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free TVTX Stock Alerts $5.45 -0.29 (-5.05%) (As of 04/24/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateMay. 2EstimatedActual EPS (Feb. 15) -$1.16 Beat By $0.11 Consensus EPS (Feb. 15) -$1.27 Get Travere Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for TVTX and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueTVTX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.TVTX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. Travere Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20244($1.20)($0.96)($1.08) Q2 20244($1.04)($0.65)($0.89) Q3 20244($0.94)($0.67)($0.82) Q4 20244($0.80)($0.51)($0.66) FY 202416($3.98)($2.79)($3.45) Q1 20251($0.34)($0.34)($0.34) Q2 20251($0.10)($0.10)($0.10) Q3 20251$0.07$0.07$0.07 Q4 20251$0.14$0.14$0.14 FY 20254($0.23)($0.23) ($0.23)TVTX Earnings Date and InformationTravere Therapeutics last issued its quarterly earnings results on February 15th, 2024. The reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.11. The business earned $45.06 million during the quarter, compared to the consensus estimate of $41.25 million. Travere Therapeutics has generated ($1.61) earnings per share over the last year (($1.61) diluted earnings per share). Earnings for Travere Therapeutics are expected to grow in the coming year, from ($3.10) to ($1.85) per share. Travere Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off prior year's report dates.Read More Travere Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/2/2024Estimated)------- 2/15/2024Q4 2023($1.27)($1.16)+$0.11($1.14)$41.25 million$45.06 million11/7/2023Q3 2023($1.09)($1.17)($0.08)($4.31)$132.01 million$37.10 million8/3/2023Q2 2023($1.16)($1.13)+$0.03($1.13)$53.93 million$59.70 million5/4/2023Q1 2023($1.18)($1.27)($0.09)($1.27)$50.93 million$56.99 million2/23/2023Q4 2022($1.04)($1.03)+$0.01($1.03)$54.80 million$55.87 million10/27/2022Q3 2022($0.97)($1.09)($0.12)($1.09)$51.32 million$53.50 million Get the Latest News and Ratings for TVTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/4/2022Q2 2022($0.94)($1.05)($0.11)($1.05)$49.33 million$54.17 million5/5/2022Q1 2022($0.85)($1.20)($0.35)($1.20)$51.92 million$48.49 million 2/24/2022Q4 2021($0.72)($0.84)($0.12)($0.84)$56.40 million$57.25 million 10/28/2021Q3 2021($0.72)($0.59)+$0.13($0.59)$60.93 million$68.20 million 7/29/2021Q2 2021($0.73)($0.64)+$0.09($0.64)$50.20 million$54.62 million 5/6/2021Q1 2021($0.56)($0.96)($0.40)($0.96)$49.99 million$47.41 million Travere Therapeutics Earnings - Frequently Asked Questions When is Travere Therapeutics's earnings date? Travere Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off last year's report dates. Learn more on TVTX's earnings history. Did Travere Therapeutics beat their earnings estimates last quarter? In the previous quarter, Travere Therapeutics (NASDAQ:TVTX) reported ($1.16) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.27) by $0.11. Learn more on analysts' earnings estimate vs. TVTX's actual earnings. How much revenue does Travere Therapeutics generate each year? Travere Therapeutics (NASDAQ:TVTX) has a recorded annual revenue of $145.24 million. How much profit does Travere Therapeutics generate each year? Travere Therapeutics (NASDAQ:TVTX) has a recorded net income of -$111.40 million. TVTX has generated -$1.61 earnings per share over the last four quarters. What is Travere Therapeutics's EPS forecast for next year? Travere Therapeutics's earnings are expected to grow from ($3.10) per share to ($1.85) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Entrada Therapeutics Earnings Theravance Biopharma Earnings Shattuck Labs Earnings Avid Bioservices Earnings Acelyrin Earnings Lexicon Pharmaceuticals Earnings IGM Biosciences Earnings Fulcrum Therapeutics Earnings Larimar Therapeutics Earnings ADC Therapeutics Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:TVTX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport Society1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
